Scholarlink

<p>Colorectal cancer (CRC) ranks as the third most prevalent malignancy and the second leading cause of cancer-related mortality globally. Despite substantial advancements in CRC therapies over recent decades, drug resistance continues to pose a significant challenge in effective treatment. This comprehensive review investigates the role of long non-coding RNAs (lncRNAs) in the emergence of drug resistance in CRC. Specifically, we analyze the functions of lncRNAs, including HOTAIR and MALAT1, in key processes such as apoptosis, DNA damage response and repair, cancer stem cell regulation, and drug metabolism. By examining the structural and biogenetic characteristics of lncRNAs, this review elucidates their specific contributions to drug resistance. We provide novel insights into the therapeutic potential of targeting lncRNAs to mitigate drug resistance in CRC, thereby offering new perspectives on treatment strategies. Ultimately, this review highlights the clinical implications of lncRNA research, emphasizing their potential as targets for innovative therapeutic interventions in colorectal cancer.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The lncrnas: innovative multifunctional players of drug resistance in colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月23日

查看全文
  • Hossein Maghsoudi,
  • Motahareh Rasoulzadeh,
  • Maryam Abbastabar,
  • Ahmad Fazilat,
  • Farhad Sheikhnia,
  • Bita Azizzadeh,
  • Mohamad Valilo,
  • Maryam Majidinia

摘要

Colorectal cancer (CRC) ranks as the third most prevalent malignancy and the second leading cause of cancer-related mortality globally. Despite substantial advancements in CRC therapies over recent decades, drug resistance continues to pose a significant challenge in effective treatment. This comprehensive review investigates the role of long non-coding RNAs (lncRNAs) in the emergence of drug resistance in CRC. Specifically, we analyze the functions of lncRNAs, including HOTAIR and MALAT1, in key processes such as apoptosis, DNA damage response and repair, cancer stem cell regulation, and drug metabolism. By examining the structural and biogenetic characteristics of lncRNAs, this review elucidates their specific contributions to drug resistance. We provide novel insights into the therapeutic potential of targeting lncRNAs to mitigate drug resistance in CRC, thereby offering new perspectives on treatment strategies. Ultimately, this review highlights the clinical implications of lncRNA research, emphasizing their potential as targets for innovative therapeutic interventions in colorectal cancer.

Graphical abstract